View Older Stories

Jun 29, 2026 03:57AM Acadia Pharmaceuticals (ACAD) PT Raised to $35 at Citi, Opens 90-Day Upside CW

Jun 26, 2026 12:33PM Oppenheimer Reiterates Perform Rating on Acadia Pharmaceuticals (ACAD)

Jun 26, 2026 10:51AM Baird Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)

Jun 26, 2026 08:09AM Mizuho Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)

May 7, 2026 06:29AM Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

May 6, 2026 04:07PM Acadia Pharma (ACAD) Misses Q1 EPS by 3c ; Offers Guidance

Apr 7, 2026 09:08AM ACADIA Pharmaceuticals launches powder formulation of Rett syndrome drug

Mar 25, 2026 06:10AM BofA Securities Upgrades Acadia Pharmaceuticals (ACAD) to Buy

Mar 24, 2026 05:54AM RBC Capital on Acadia Pharmaceuticals (ACAD): 'Setup Skews Net Favorably'

Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'

Mar 2, 2026 04:57PM Acadia Pharmaceuticals (ACAD) PT Lowered to $29 at BofA Securities

Mar 2, 2026 04:56PM Acadia Pharmaceuticals (ACAD) PT Lowered to $29 at BofA Securities

Mar 2, 2026 04:05PM Acadia Pharmaceuticals plans re-examination after EU rejection of Rett drug

Feb 26, 2026 07:51AM Acadia Pharmaceuticals (ACAD) PT Raised to $20 at Jefferies

Feb 26, 2026 06:58AM Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Citi

Feb 26, 2026 04:37AM Acadia Pharmaceuticals (ACAD) PT Raised to $35 at Citizens: Potential for Robust Growth

Feb 25, 2026 04:16PM Acadia Pharma (ACAD) Tops Q4 EPS by 146c ; Offers Guidance

Feb 24, 2026 09:01AM Wolfe Research Starts Acadia Pharmaceuticals (ACAD) at Outperform

Feb 23, 2026 03:32PM Acadia Pharma (ACAD) call put ratio 37 calls to 1 put with a focus on March calls as share price up 1.4%

Feb 23, 2026 04:41AM Mizuho Upgrades Acadia Pharmaceuticals (ACAD) to Outperform

Feb 6, 2026 06:31AM Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer

Feb 3, 2026 08:48AM Acadia Pharmaceuticals (ACAD) PT Lowered to $31 at RBC Capital

Feb 3, 2026 06:43AM H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

Feb 3, 2026 06:36AM Canaccord Genuity Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

Feb 3, 2026 04:11AM Acadia Pharmaceuticals (ACAD) Reiterated at Market Outperform by Citizens

Feb 2, 2026 04:14PM ACADIA receives negative trend vote from EU regulators on Rett drug

Jan 27, 2026 06:58AM Canaccord Genuity Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

Jan 13, 2026 04:02PM Acadia Pharma anticipates 2025 net sales to exceed $1 billion

Jan 13, 2026 09:02AM ACADIA projects $1.7 billion in 2028 sales, launches new DAYBUE formulation

Jan 5, 2026 07:08AM Needham Names MindMed (MNMD) New Top Pick for 2026, Adds to Conviction List

Dec 16, 2025 06:52AM Acadia Pharmaceuticals (ACAD) PT Raised to $37 at H.C. Wainwright

Dec 11, 2025 07:31AM Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Stifel

Dec 4, 2025 09:52AM Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at UBS, Stock Still a 'Top Idea'

Dec 2, 2025 04:32AM Acadia Pharmaceuticals (ACAD) PT Raised to $29 at Mizuho

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 12, 2025 04:04AM Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at RBC Capital

Nov 6, 2025 04:30AM Acadia Pharmaceuticals (ACAD) PT Lowered to $32 at RBC Capital

Nov 5, 2025 04:19PM Acadia Pharma (ACAD) Tops Q3 EPS by 28c, provides guidance

Nov 3, 2025 04:26PM ACADIA Pharmaceuticals board member Daniel Soland resigns

Oct 21, 2025 05:01AM Citi Starts Acadia Pharmaceuticals (ACAD) at Buy

Oct 12, 2025 03:00PM Biotech stocks: Q3 earnings preview

Oct 8, 2025 06:42AM Mizuho Reiterates Neutral Rating on Acadia Pharmaceuticals (ACAD)

Oct 2, 2025 09:05AM Acadia Pharmaceuticals to present clinical data at movement disorders congress

Sep 25, 2025 08:50AM BMO Capital Cuts Acadia Pharmaceuticals (ACAD) Stock PT Following ACP-101 Miss

Sep 24, 2025 03:41PM Acadia Pharmaceuticals (ACAD) PT Lowered to $21 at Oppenheimer

Sep 24, 2025 03:38PM Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at TD Cowen

Sep 24, 2025 10:25AM Leerink on Acadia (ACAD): 'Despite the news, we still like the stock'

Sep 24, 2025 10:23AM BofA Son Acadia (ACAD): 'our focus continues to be on the reacceleration of the Daybue launch in Rett syndrome'

Sep 24, 2025 09:29AM Baird: 'Acadia shares should come out relatively unscathed after the dust settles'

Sep 24, 2025 08:26AM ACAD failure eliminates a competitive threat to Soleno Therapeutics (SLNO) - Oppenheimer

View Older Stories